23 results on '"Gordon Ford"'
Search Results
2. Optimizing Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease – Practical Issues: A Canadian Thoracic Society Clinical Practice Guideline
- Author
-
Darcy D Marciniuk, Dina Brooks, Scott Butcher, Richard Debigare, Gail Dechman, Gordon Ford, Veronique Pepin, Darlene Reid, Andrew W Sheel, Micheal K Stickland, David C Todd, Shannon L Walker, Shawn D Aaron, Meyer Balter, Jean Bourbeau, Paul Hernandez, Francois Maltais, Denis E O’Donnell, Donna Bleakney, Brian Carlin, Roger Goldstein, and Stella K Muthuri
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Pulmonary rehabilitation (PR) participation is the standard of care for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite bronchodilator therapies. However, there are questions about specific aspects of PR programming including optimal site of rehabilitation delivery, components of rehabilitation programming, duration of rehabilitation, target populations and timing of rehabilitation. The present document was compiled to specifically address these important clinical issues, using an evidence-based, systematic review process led by a representative interprofessional panel of experts.
- Published
- 2010
- Full Text
- View/download PDF
3. Les Lignes Directrices de la Société Canadienne de Thoracologie pour la MPOC: Un Résumé des Recommendations à l'Intention des Médecins de Famille
- Author
-
Denis E O'Donnell, Paul Hernandez, Shawn Aaron, Jean Bourbeau, Darcy Marciniuk, Rick Hodder, Meyer Balter, Gordon Ford, André Gervais, Roger Goldstein, François Maltais, Jeremy Road, Valoree McKay, and Jennifer Schenkel
- Subjects
Diseases of the respiratory system ,RC705-779 - Published
- 2003
- Full Text
- View/download PDF
4. Canadian Thoracic Society COPD Guidelines: Summary of Highlights for Family Doctors
- Author
-
Denis E O'Donnell, Paul Hernandez, Shawn Aaron, Jean Bourbeau, Darcy Marciniuk, Rick Hodder, Meyer Balter, Gordon Ford, Andre Gervais, Roger Goldstein, Francois Maltais, Jeremy Road, Valoree McKay, and Jennifer Schenkel
- Subjects
Diseases of the respiratory system ,RC705-779 - Published
- 2003
- Full Text
- View/download PDF
5. Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease – 2008 Update – Highlights for Primary Care
- Author
-
Denis E O’Donnell, Paul Hernandez, Alan Kaplan, Shawn Aaron, Jean Bourbeau, Darcy Marciniuk, Meyer Balter, Gordon Ford, Andre Gervais, Yves Lacasse, Francois Maltais, Jeremy Road, Graeme Rocker, Don Sin, Tasmin Sinuff, and Nha Voduc
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Chronic obstructive pulmonary disease (COPD) is a major respiratory illness in Canada that is preventable and treatable but unfortunately remains underdiagnosed. The purpose of the present article from the Canadian Thoracic Society is to provide up-to-date information so that patients with this condition receive optimal care that is firmly based on scientific evidence. Important summary messages for clinicians are derived from the more detailed Update publication and are highlighted throughout the document. Three key messages contained in the update are: use targeted screening spirometry to establish a diagnosis and initiate prompt management (including smoking cessation) of mild COPD; improve dyspnea and activity limitation in stable COPD using new evidence-based treatment algorithms; and understand the importance of preventing and managing acute exacerbations, particularly in moderate to severe disease.
- Published
- 2008
- Full Text
- View/download PDF
6. Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease – 2007 Update
- Author
-
Denis E O’Donnell, Shawn Aaron, Jean Bourbeau, Paul Hernandez, Darcy D Marciniuk, Meyer Balter, Gordon Ford, Andre Gervais, Roger Goldstein, Rick Hodder, Alan Kaplan, Sean Keenan, Yves Lacasse, Francois Maltais, Jeremy Road, Graeme Rocker, Don Sin, Tasmin Sinuff, and Nha Voduc
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Chronic obstructive pulmonary disease (COPD) is a major respiratory illness in Canada that is both preventable and treatable. Our understanding of the pathophysiology of this complex condition continues to grow and our ability to offer effective treatment to those who suffer from it has improved considerably. The purpose of the present educational initiative of the Canadian Thoracic Society (CTS) is to provide up to date information on new developments in the field so that patients with this condition will receive optimal care that is firmly based on scientific evidence. Since the previous CTS management recommendations were published in 2003, a wealth of new scientific information has become available. The implications of this new knowledge with respect to optimal clinical care have been carefully considered by the CTS Panel and the conclusions are presented in the current document. Highlights of this update include new epidemiological information on mortality and prevalence of COPD, which charts its emergence as a major health problem for women; a new section on common comorbidities in COPD; an increased emphasis on the meaningful benefits of combined pharmacological and nonpharmacological therapies; and a new discussion on the prevention of acute exacerbations. A revised stratification system for severity of airway obstruction is proposed, together with other suggestions on how best to clinically evaluate individual patients with this complex disease. The results of the largest randomized clinical trial ever undertaken in COPD have recently been published, enabling the Panel to make evidence-based recommendations on the role of modern pharmacotherapy. The Panel hopes that these new practice guidelines, which reflect a rigorous analysis of the recent literature, will assist caregivers in the diagnosis and management of this common condition.
- Published
- 2007
- Full Text
- View/download PDF
7. State of the Art Compendium: Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease
- Author
-
Denis E O’Donnell, Shawn Aaron, Jean Bourbeau, Paul Hernandez, Darcy Marciniuk, Meyer Balter, Gordon Ford, Andre Gervais, Roger Goldstein, Rick Hodder, Francois Maltais, and Jeremy Road
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Chronic obstructive pulmonary disease (COPD) is a common cause of disability and death in Canada. Moreover, morbidity and mortality from COPD continue to rise, and the economic burden is enormous. The main goal of the Canadian Thoracic Society’s evidence-based guidelines is to optimize early diagnosis, prevention and management of COPD in Canada. The main message of the guidelines is that COPD is a preventable and treatable disease. Targeted spirometry is strongly recommended to expedite early diagnosis in smokers and former smokers who develop respiratory symptoms, and who are at risk for COPD. Smoking cessation remains the single most effective intervention to reduce the risk of COPD and to slow its progression. Education, especially self-management plans, are key interventions in COPD. Therapy should be escalated on an individual basis in accordance with the increasing severity of symptoms and disability. Long-acting anticholinergics and beta-2-agonist inhalers should be prescribed for patients who remain symptomatic despite short-acting bronchodilator therapy. Inhaled steroids should not be used as first line therapy in COPD, but have a role in preventing exacerbations in patients with more advanced disease who suffer recurrent exacerbations. Acute exacerbations of COPD cause significant morbidity and mortality and should be treated promptly with bronchodilators and a short course of oral steroids; antibiotics should be prescribed for purulent exacerbations. Patients with advanced COPD and respiratory failure require a comprehensive management plan that incorporates structured end-of-life care. Management strategies, consisting of combined modern pharmacotherapy and nonpharmacotherapeutic interventions (eg, pulmonary rehabilitation and exercise training) can effectively improve symptoms, activity levels and quality of life, even in patients with severe COPD.
- Published
- 2004
- Full Text
- View/download PDF
8. Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease – 2003
- Author
-
Denis E O’donnell, Shawn Aaron, Jean Bourbeau, Paul Hernandez, Darcy D Marciniuk, Meyer Balter, Gordon Ford, Andre Gervais, Roger Goldstein, Rick Hodder, Francois Maltais, and Jeremy Road
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Chronic obstructive pulmonary disease (COPD) is a common cause of disability and death in Canada. Moreover, morbidity and mortality from COPD continue to rise and the economic burden is enormous. The main goal of the Canadian Thoracic Society (CTS) Evidence-Based Guidelines is to optimize early diagnosis, prevention and management of COPD in Canada. Targeted spirometry is strongly recommended to expedite early diagnosis in smokers and exsmokers who develop respiratory symptoms, and who are at risk for COPD. Smoking cessation remains the single most effective intervention to reduce the risk of COPD and to slow its progression. Education, especially self-management plans, are key interventions in COPD. Therapy should be escalated in accordance with the increasing severity of symptoms and disability. Long acting anticholinergics and beta2-agonist inhalers should be prescribed for patients who remain symptomatic despite short-acting bronchodilator therapy. Inhaled steroids should not be used as first line therapy in COPD, but have a role in preventing exacerbations in patients with more advanced disease who suffer recurrent exacerbations. Management strategies consisting of combined modern pharmacotherapy and nonpharmacotherapeutic interventions (eg, pulmonary rehabilitation/exercise training) can effectively improve symptoms, activity levels, and quality of life, even in patients with severe COPD. Acute exacerbations of COPD cause significant morbidity and mortality and should be treated promptly with bronchodilators and a short course of oral steroids; antibiotics should be prescribed for purulent exacerbations. Patients with advanced COPD and respiratory failure require a comprehensive management plan that incorporates structured end-of-life care.
- Published
- 2003
- Full Text
- View/download PDF
9. The CTS needs you! Participate in our strategic planning process to direct the CTS’s future and to help us help you
- Author
-
Gordon Ford
- Subjects
Diseases of the respiratory system ,RC705-779 - Published
- 2006
- Full Text
- View/download PDF
10. Summer Musings 2006 – Join Me October 21 to 26 at CTS 2006/CHEST 2006
- Author
-
Gordon Ford
- Subjects
Diseases of the respiratory system ,RC705-779 - Published
- 2006
- Full Text
- View/download PDF
11. 2005/2006 – Highlights of a Successful Year!
- Author
-
Gordon Ford
- Subjects
Diseases of the respiratory system ,RC705-779 - Published
- 2006
- Full Text
- View/download PDF
12. Bitter Fruit: Dysfunction and Abuse in the Local Church
- Author
-
Keith Gordon Ford and Keith Gordon Ford
- Published
- 2021
13. Flexure-Ring for Centering a Concave Lens in a Bore of a Housing for an Optical System
- Author
-
Viriginia Gordon Ford
- Subjects
Optics - Abstract
A flexure-ring is provided for centering a lens in a bore of a housing with 3N lens contacting stubs, where N is an integer equal to or greater than one. The stubs are formed by increasing the inside diameter of the ring made to fit tightly around a lens except at 3N locations for the aforesaid stubs, and said ring having an outside diameter made to fit tightly inside the housing bore locations. Behind each stub, a segment of the ring is removed down to a chord perpendicular to a ring diameter passing through the center of each stub. That chord is selected to have a length greater than the lens contacting surface of the stub, thereby to produce a reduced cross section of the ring on both sides of the stub to serve as flexures in relieving stresses due to different coefficients of thermal expansion of the three parts involved due to changes in temperature while in use.
- Published
- 2002
14. The Effects of Fluticasone with or without Salmeterol on Systemic Biomarkers of Inflammation in Chronic Obstructive Pulmonary Disease
- Author
-
Don D, Sin, S F Paul, Man, Darcy D, Marciniuk, Gordon, Ford, Mark, FitzGerald, Eric, Wong, Ernest, York, Rajesh R, Mainra, Warren, Ramesh, Lyle S, Melenka, Eric, Wilde, Robert L, Cowie, Dave, Williams, Wen Q, Gan, Roxanne, Rousseau, and Gerry, Hagan
- Subjects
Male ,Pulmonary and Respiratory Medicine ,Canada ,medicine.medical_specialty ,medicine.drug_class ,Anti-Inflammatory Agents ,Critical Care and Intensive Care Medicine ,Systemic inflammation ,Gastroenterology ,Pulmonary Disease, Chronic Obstructive ,Double-Blind Method ,Intensive care ,Internal medicine ,Bronchodilator ,Administration, Inhalation ,medicine ,Clinical endpoint ,Humans ,Albuterol ,Aged ,Fluticasone ,COPD ,Interleukin-6 ,business.industry ,Adrenergic beta-Agonists ,Middle Aged ,Pulmonary Surfactant-Associated Protein D ,medicine.disease ,Fluticasone-Salmeterol Drug Combination ,Respiratory Function Tests ,Androstadienes ,Drug Combinations ,C-Reactive Protein ,Treatment Outcome ,Anesthesia ,Corticosteroid ,Female ,Salmeterol ,medicine.symptom ,business ,Biomarkers ,medicine.drug - Abstract
Small studies have suggested that inhaled corticosteroids can suppress systemic inflammation in chronic obstructive pulmonary disease (COPD).To determine the effect of inhaled corticosteroids with or without long-acting beta(2)-adrenergic agonist on systemic biomarkers of inflammation.We conducted a double-blind randomized placebo-controlled trial across 11 centers (n = 289 patients with FEV(1) of 47.8 +/- 16.2% of predicted) to compare the effects of inhaled fluticasone alone or in combination with salmeterol against placebo on circulating biomarkers of systemic inflammation over 4 weeks. The primary endpoint was C-reactive protein (CRP) level. Secondary molecules of interest were IL-6 and surfactant protein D (SP-D).Neither fluticasone nor the combination of fluticasone/salmeterol had a significant effect on CRP or IL-6 levels. There was, however, a significant reduction in SP-D levels with fluticasone and fluticasone/salmeterol compared with placebo (P = 0.002). Health status also improved significantly in both the fluticasone and fluticasone/salmeterol groups compared with placebo, driven mostly by improvements in the symptom scores. Changes in the circulating SP-D levels were related to changes in health status scores. FEV(1) improved significantly only in the fluticasone/salmeterol group compared with placebo.ICS in conjunction with long-acting beta(2)-adrenergic agonist do not reduce CRP or IL-6 levels in serum of patients with COPD over 4 weeks. They do, however, significantly reduce serum SP-D levels. These data suggest that these drugs reduce lung-specific but not generalized biomarkers of systemic inflammation in COPD.
- Published
- 2008
15. Characterization of Ypr1p fromSaccharomyces cerevisiae as a 2-methylbutyraldehyde reductase
- Author
-
Gordon Ford and Elizabeth M. Ellis
- Subjects
Saccharomyces cerevisiae Proteins ,Saccharomyces cerevisiae ,Aldo-Keto Reductases ,Bioengineering ,Alcohol oxidoreductase ,Reductase ,Applied Microbiology and Biotechnology ,Biochemistry ,Hexanal ,Substrate Specificity ,chemistry.chemical_compound ,Aldehyde Reductase ,Osmotic Pressure ,Genetics ,chemistry.chemical_classification ,Aldehydes ,Aldo-keto reductase ,biology ,biology.organism_classification ,Yeast ,Alcohol Oxidoreductases ,Kinetics ,Oxidative Stress ,Enzyme ,chemistry ,Glycerol dehydrogenase ,Gene Deletion ,Sugar Alcohol Dehydrogenases ,Biotechnology - Abstract
The metabolism of aldehydes and ketones in yeast is important for biosynthetic, catabolic and detoxication processes. Aldo-keto reductases are a family of enzymes that are able to reduce aldehydes and ketones. The roles of individual aldo-keto reductases in yeast has been difficult to determine because of overlapping substrate specificities of these enzymes. In this study, we have cloned, expressed and characterized the aldo-keto reductase Ypr1p from the yeast Saccharomyces cerevisiae and we describe its substrate specificity. The enzyme displays high specific activity towards 2-methylbutyraldehyde, as well as other aldehydes such as hexanal. It exhibits extremely low activity as a glycerol dehydrogenase. The enzyme functions over a wide pH range and uses NADPH as co-factor. In comparison to other mammalian and yeast aldo-keto reductases, Ypr1p has relatively high affinity for D,L-glyceraldehyde (1.08 mM) and hexanal (0.39 mM), but relatively low affinity for 4-nitrobenzaldehyde (1.07 mM). It displays higher specific activity for 2-methylbutyraldehyde than does yeast alcohol dehydrogenase and has a K(m) for 2-methyl butyraldehyde of 1.09 mM. The enzyme is expressed during growth on glucose, but its levels are rapidly induced by osmotic and oxidative stress. Yeast in which the YPR1 gene has been deleted possess 50% lower 2-methylbutyraldehyde reductase activity than the wild-type strain. This suggests that the enzyme may contribute to 2-methyl butyraldehyde reduction in vivo. It may therefore play a role in isoleucine catabolism and fusel alcohol formation and may influence flavour formation by strains of brewing yeast.
- Published
- 2002
16. Three aldo–keto reductases of the yeast Saccharomyces cerevisiae
- Author
-
Gordon Ford and Elizabeth M. Ellis
- Subjects
Molecular Sequence Data ,Saccharomyces cerevisiae ,Aldo-Keto Reductases ,Gene Expression ,Toxicology ,Isozyme ,Genome ,Aldehyde Reductase ,Animals ,Amino Acid Sequence ,Cloning, Molecular ,Gene ,DNA Primers ,Genetics ,Base Sequence ,Sequence Homology, Amino Acid ,biology ,Gene targeting ,General Medicine ,biology.organism_classification ,Yeast ,Rats ,Isoenzymes ,Gene expression profiling ,Alcohol Oxidoreductases ,Kinetics ,Open reading frame ,Biochemistry ,Gene Targeting ,Genome, Fungal - Abstract
Saccharomyces cerevisiae is an industrially important yeast, which is also used extensively as a model eukaryote. The S. cerevisiae genome has been sequenced in its entirety and therefore represents an ideal organism in which to carry out functional analysis of genes. We have identified several open reading frames in the S. cerevisiae genome which show significant similarity to members of the aldo-keto reductase superfamily. The physiological roles of these gene products have not been previously determined, but their similarity to other enzymes suggests they may perform roles in carbohydrate metabolism and detoxification pathways. Cloning and expression of three of these enzymes has allowed their substrate specificities to be determined. Expression profiling and gene disruption analysis will allow potential roles for these enzymes within the cell to be examined.
- Published
- 2001
17. Prolonged and Multipatient Use of Prefilled Disposable Oxygen Humidifier Bottles: Safety and Cost
- Author
-
Walter Krulicki, Linda Sutherland, Karen Hume, Thomas J. Louie, Karen Hope, Elizabeth Henderson, Donna Ledgerwood, Gordon Ford, and Sandy Golar
- Subjects
0301 basic medicine ,Microbiology (medical) ,Cross Infection ,Epidemiology ,business.industry ,Patient risk ,030106 microbiology ,Oxygen Inhalation Therapy ,Humidifiers ,Hospital Bed Capacity, 500 and over ,Alberta ,Cost savings ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Anesthesia ,Costs and Cost Analysis ,Cost analysis ,Equipment Contamination ,Humans ,Medicine ,030212 general & internal medicine ,Disposable Equipment ,business - Abstract
Objective:Multipatient use and prolonged use of prefilled disposable oxygen humidifier bottles (Aquapak 301, Respiratory Care, Inc., Arlington Heights, IL) were evaluated by performing microbiologic monitoring and a cost analysis on bottles used for varying numbers of patients and lengths of time.Methods:Humidifiers were hung for a maximum of one month. Monitoring was conducted in 6 different nursing areas. Quantitative cultures were done for aerobes and Legionella. Reusable humidifier bottles also were monitored.Results:Cultures were obtained from 1,311 disposable and 60 reusable humidifiers. No significant bacterial contamination was detected in the prefilled disposable oxygen humidifier units. Ten percent of the reusable bottles were contaminated by organisms associated with skin flora.Conclusions:Multipatient use and increased duration of use of disposable humidifiers result in cost savings without increasing patient risk. Restricted multipatient use of prefilled disposable oxygen humidifier bottles for a period of one month is a safe and cost-efficient practice.
- Published
- 1993
18. Contributors
- Author
-
Nabih I. Abdou, Kathryn M. Abel, Judith A. Aberg, Diann M. Ackard, Jonathan D. Adachi, Jill Aimee Addesa, Robert J. Agate, Jerilyn Allen, Shilpa H. Amin, Aristotelis G. Anastasiadis, David E. Anderson, Gaya Aranoff, Arthur P. Arnold, Craig S. Atwood, Casilda Balmaceda, Promila Banerjee, Jamie S. Barkin, Shari S. Bassuk, David Bateman, Carolyn Becker, Jennifer Bell, Robert R. Bies, Kristin L. Bigos, Kathryn L. Bilello, John P. Bilezikian, Candice Bjornson, Jerry G. Blaivas, Roger S. Blumenthal, Roger Bouillon, Richard Bowen, Kimberly T. Brill, Ronald T. Burkman, William Byne, Leigh Ann Callahan, Marcia Irene Canto, Laura L. Carruth, Donald O. Castell, Lin Chang, Min C. Chen, Margaret A. Chesney, Mary Ann Chiasson, Pierre Chue, Pak Chung, Wendy K. Chung, Darryl S. Chutka, Costanza Cocilovo, Marcia L. Collaer, Hari S. Conjeevaram, Robert W. Coombs, Ann M. Coulston, Ann Cranney, Marcia Cruz-Correa, Carolyn D'Ambrosio, Kristin L. Dardano, Sai Krupa Das, L. Eugene Daugherty, Anne R. Davis, Lillian G. Dawes, Wendy Demark-Wahnefried, Dawn L. DeMeo, Dickson D. Despommier, Pamela S. Douglas, Dmitry Droggin, Catherine E. DuBeau, Alison M. Duncan, Dayna Early, Wafaa El-Sadr, Jose Erbella, William S. Evans, Kevin C. Fleming, Adam J. Flisser, David Fogelman, Gordon Ford, Susan C. Fox, Amy Foxx-Orenstein, Marilynn C. Frederiksen, James H. Garvin, John P. Gearhart, Claudia L. Ginsberg, Marc Goldstein, Raquel E. Gur, Ruben C. Gur, Christine A. Haller, Scott M. Hammer, Lynn C. Hartmann, Christine M. Hay, Megan Rist Haymart, Margaret M. Heitkemper, Dawn Hershman, Daniel L. Hogan, Carin V. Hopps, Shiew-Mei Huang, Stacy D. Jacobson, James Joseph, Gary M. Kammer, Robyn G. Karlstadt, Umaprasanna S. Karnam, Sonya Kashyap, David M. Kaufman, Steven R. Kayser, Sundeep Khosla, Nigar Kirmani, David Knopman, Tatjana Kolevska, Laurence N. Kolonel, Carol L. Kuhle, Mindy S. Kurzer, Robert G. Lahita, George M. Lazarus, Susan J. Lee, Marianne J. Legato, Jaswinder K. Legha, Lawrence J. Lesko, Jon D. Levine, Li-Ming Loh, Anne C. Looker, Franklin D. Lowy, Susmita Mallik, JoAnn E. Manson, Dawn A. Marcus, Antonio Martin, Richard A. Matthay, R. Scott McClelland, Mary Gail Mercurio, Jordan D. Metzl, Christine Miaskowski, Margaret Miller, Paul D. Miller, Jeffrey W. Milsom, Ian Mitchell, Karen L. Moncher, Lisa Moores, Martha J. Morrell, Susan Murin, Caitlin M. Nass, Alfred I. Neugut, Gwen L. Nichols, Colm J. O'Loughlin, Albert M. Ong, Jose M. Ordovas, Katherine M.A. O'Reilly, Kyriakos Papadopoulos, Alexandra Papaioannou, Ann L. Parke, George Perry, Thai Pham, William R. Phipps, Anthony P. Pietropaoli, Bruce G. Pollock, William G. Powderly, Vijaya S. Pratha, Deborah Denise Proctor, Sandhya Pruthi, Timothy J. Ramsden, Sarathchandra I. Reddy, Virginia Rider, Ellen Ritchie, Barbara H. Roberts, Susan B. Roberts, Cheryl L. Rock, Lauri Romanzi, Giuseppe M.C. Rosano, Melissa Rose, Michael R. Rosen, Tove S. Rosen, Zachary Rosner, Jennifer Rossi, Mishaela R. Rubin, Mack T. Ruffin, Donna Russo, Chandra Sahajwalla, Laurent Salomon, Hilary Sanfey, Philip M. Sarrel, Peter N. Schlegel, Janice B. Schwartz, Mary V. Seeman, Annabell C. Segarra, Christina Sekaer, Meredith Selleck, Ridwan Shabsigh, Beverley J. Sheares, Donna Shoupe, Lee P. Shulman, Edwin K. Silverman, Patricia J. Sime, Mark A. Smith, Magdalena E. Sobieszczyk, Toyooki Sonoda, Edward J. Stanford, Donald G. Stein, Richard C. Sullivan, Gerald Supinski, Maged Tanios, Mark A. Tarnopolsky, Robert Temple, Amy Tiersten, Theresa Toigo, Heather O. Tory, David R. Trawick, Simon J. Tsiouris, Marisa Tungsiripat-Gerber, Viola Vaccarino, Mark C. Valkenburgh, Dirk Vanderschueren, Johannes D. Veldhuis, Katrien Venken, Sara E. Walker, Myron L. Weisfeldt, Jeffrey P. Weiss, Timothy Wilkin, Jacqueline L. Wolf, C.R.J. Woodhouse, Michael Yin, Cosmina Zeana, and Naseem Zojwalla
- Published
- 2004
19. Support for suspended surgeon
- Author
-
Patricia Gudgeon, Arun Gandhi, Haley Mathew, David J. Lloyd, Paul Coulden, Anthony Tucker, John Shea, Victor Moore, Oxana Maher, Bas Ikoku, Peter W Angus, John Thomlinson, Ranjan Kundu, Mallika Mohanraj, Peter W. James, Patrick Ahfat, William Case, Susan Barnes, Eileen Stickley, Arun Mishra, Michael Lynch, Gillian Wilson, Chandan Biswas, John Wetherill, Tom Kemp, Gordon Ford, Penny Smith, Clair Logan, Sarah Brayshaw, Kaly Bhabra, and Margaret Jane Evans
- Subjects
Text mining ,Computer science ,business.industry ,General Engineering ,General Earth and Planetary Sciences ,General Medicine ,Letters ,business ,Data science ,General Environmental Science - Published
- 1992
20. Prolonged, Multipatient Use of Oxygen Humidifier Bottles
- Author
-
Elizabeth Henderson, Charles Salemi, Gary Mermilliod, Pam Hansen, and Gordon Ford
- Subjects
Microbiology (medical) ,Oxygen inhalation therapy ,Infection Control ,Epidemiology ,business.industry ,Nebulizers and Vaporizers ,Oxygen Inhalation Therapy ,chemistry.chemical_element ,Oxygen ,Cost savings ,Infectious Diseases ,chemistry ,Cost Savings ,Anesthesia ,Infection control ,Humans ,Medicine ,Disposable Equipment ,business - Published
- 1994
21. Pityrosporon folliculitis
- Author
-
Gordon Ford
- Subjects
Adult ,Folliculitis ,Ketoconazole ,Malassezia ,Dermatomycoses ,Humans ,Dermatology - Published
- 1984
22. Instrumental improvements of rapid, detailed kinetic studies of oxygenase activity
- Author
-
Harold W. Cook, William E. M. Lands, and Gordon Ford
- Subjects
Polarography ,Chromatography ,Chemistry ,Microchemistry ,Biophysics ,Analytical chemistry ,chemistry.chemical_element ,Cell Biology ,Biochemistry ,Oxygen ,law.invention ,Differentiator ,Kinetics ,Membrane ,law ,Spectrophotometry ,Electrode ,Oxygenases ,Limiting oxygen concentration ,Sensitivity (control systems) ,Molecular Biology ,Clark electrode ,Electrodes - Abstract
The characteristics of an electronic differentiator that facilitates continuous monitoring of changes in the oxygen concentration measured by a polarographic oxygen electrode are described. In addition, some properties of the electrode membranes that increase the sensitivity of the oxygen-sensing electrode are also described. These modifications greatly improve the accuracy and sensitivity of the biological oxygen monitor for use in kinetic studies of complex enzyme systems such as soybean lipoxygenase or prostaglandin cyclooxygenase. The electronic differentiator also may be used in conjunction with other ratemonitoring instruments such as spectrophotometers and pH meters for accurate quantitation of rapidly changing rates.
- Published
- 1979
23. Is it more effective for national regulators to go directly to the city level to enforce environmental laws?
- Author
-
Tan Z, Yan L, and Chan KC
- Abstract
We examine the effectiveness of a new approach of using a direct inspection program on all environmental laws on the firm-level environmental investment in China. The direct inspection program is a response to the continued pollution issues despite the increased effort in the actions of regulatory agencies and their agents. Our findings suggest that firms located in direct inspection cities perform better than those located in non-direct inspection cities in terms of environmental investments. The findings are robust to a battery of robustness checks. Using dynamic analysis, we find that the effect of the direct inspection program lasts at least two years. Our further analysis shows that firms in direct inspection cities respond better to environmental enforcement and non-stated owned firms receive more subsidies than firms in non-direct inspection program cities. The major take away from our analysis is that, in emerging economies, it is more effective to go directly to the city level to enhance the actions of regulatory agencies and their agents. Cutting layers of agencies can enhance firm-level environmental investment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.